adrian-s-sflive.jpg

SF.Live Highlights – Giving a Risk Provider Focus

SF.Live Highlights – Giving a Risk Provider Focus

Adrian Sargent, Managing Director & Founder, ESG Treasury, speaks off the back of SF.Live's Re-Imagining Risk Modelling for Sustainable Finance Co-Creation Workshop about his key takeaways from the event.

Top Stock Picks – Chasing 10x Return in Gold, Silver, Lead & Zinc


#SFLive Ep 153 with Emanuel Ajay Datt, Prinicpal & Founder of Datt Capital discussing his funds success, capital allocation, commodity trends, Adriatic Metals & his Top Picks.
▼▼▼ EXPAND FOR MORE INFORMATION ▼▼▼

#GOLD #SILVER
MAKE SURE TO SUBSCRIBE TO OUR CHANNEL & HIT THE ALERT BUTTON

Also, follow us on www.twitter.com/soarfinancial – make sure to follow us & click on the bell icon!

Please find more information at
https://www.datt.com.au/

►► Follow Us! ◄◄
Twitter: http://twitter.com/soarfinancial
Instagram: https://www.instagram.com/soarfinancial/
Facebook: https://www.facebook.com/soarfinanctial/
Website: http://www.soarfinancial.com

SF Live is a new format by Soar Financial Partners. The goal is to give short company updates and more importantly get investors engaged directly with the companies.

Intro Music: “Summer” by Bensound.com

Disclaimer:

Unless specifically disclosed, all information available on Soar Financial and its affiliates or partners should be considered as non-commercial in nature. None of the content produced by Soar Financial should be considered an endorsement, offer or recommendation to buy or sell securities. Soar Financial is not registered with any financial or securities regulatory authority in Canada, the US, Europe, or the UK, and does not provide, nor claim to provide, investment advice or recommendations to any consumer of the content that Soar Financial produces and publicizes. Always do your own due diligence and/or consult a qualified legal, tax, or investment professional if personal advice is deemed necessary.

Soar Financial and its related companies (including its directors, employees, and representatives) or a connected person may hold equity positions in securities detailed in communications. When this occurs a disclosure will be made. Disclosures on social media will be made using the hashtag #coi (short for conflict of interest).

Soar Financial, its affiliates, and their respective directors, officers, employees, or agents expressly disclaim any liability for losses or damages, whether direct, indirect, special, or consequential, or other consequences, howsoever caused, arising out of any use or reproduction of this site or any decision made or action taken in reliance upon the produced content of Soar Financial, whether authorized or not. By accessing Soar Financial’s content, each consumer of Soar Financials content releases Soar Financial, its affiliates, and their respective officers, directors, agents, and employees from all claims and proceedings for such losses, damages, or consequences.

Soar Financial may provide content on third-party sites and we disclaim any responsibility for the content of any information posted on such other websites.

#mining #exploration #debt #financing #investing #investment #stocks #goldprice #inflation #wealth #FED #moneyprinting #silver #gold #wallstreetbets #silversqueeze #wsb #hold

Perioperative strategies to optimize long term neurodevelopment in pediatric cardiac patients

Dr. Dale Bredesen on Preventing and Reversing Alzheimer’s Disease


Dale E. Bredesen, M.D., is a professor of neurology at the Easton Laboratories for Neurodegenerative Disease Research at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

Dr. Bredesen’s laboratory focuses on identifying and understanding basic mechanisms underlying the neurodegenerative process and the translation of this knowledge into effective treatments for Alzheimer’s disease and other neurodegenerative conditions. He has collaborated on the publication of more than 220 academic research papers.

His work has culminated in the development of a protocol called ReCODE – reversal of cognitive decline – currently used by over 3,000 patients with the goal of not just preventing, but reversing Alzheimer’s disease and mild cognitive impairment.

▶︎ Get the episode’s show notes and transcript.
https://www.foundmyfitness.com/episodes/dale-bredesen

Chapters
00:00:00 – Introduction
00:00:53 – Alzheimer’s
00:02:06 – Amyloid-��
00:04:22 – Alzheimer types
00:09:29 – Zinc &Copper
00:13:49 – APOE-4
00:15:48 – Cognoscopy
00:18:13 – Lifestyle interventions
00:20:30 – Homocysteine
00:21:54 – Hemoglobin A1C
00:23:11 – Hormones
00:25:30 – Toxins
00:27:10 – Diet
00:28:47 – Mercury
00:31:07 – Keto-diet
00:42:22 – Amyloid plaque clearance
00:45:51 – Omega-3
00:50:48 – Herpes
00:52:27 – Sauna
00:56:01 – Removing amyloid
01:00:59 – Available tests

▶︎ Learn more about Dr. Bredesen’s ReCODE protocol.
https://www.ahnphealth.com/inform.html

▶︎ Get Dr. Bredesen’s New York Times and Wallstreet Journal best selling book The End of Alzheimer’s.
https://amzn.to/2R9rfIn

▶︎ Did you enjoy this podcast? It was brought to you by people like you! Become a member of the community by supporting the podcast with your own pay-what-you-can subscription.
https://www.foundmyfitness.com/crowdsponsor

▶︎ Submit your raw genetic data. You can find the APOE report at https://www.foundmyfitness.com/genetics.

Why Monkeypox Is a Global Health Threat | WSJ


What smallpox is to humans — monkeypox is to animals. So what happens when a human is infected with an animal disease? WSJ explains the symptoms, reactions and treatment of a monkeypox infection.

Read more about what you need to know about the 2022 monkeypox outbreak on The Wall Street Journal: https://www.wsj.com/articles/monkeypox-outbreak-symptoms-contagious-treatment-vaccine-11652984213

Illustration: Adele Morgan

More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Visit the WSJ Video Center: https://wsj.com/video

On Facebook: https://www.facebook.com/pg/wsj/videos/
On Twitter: https://twitter.com/WSJ
On Snapchat: https://on.wsj.com/2ratjSM

#Monkeypox #WSJ